Pear Therapeutics
Pear discovers, develops, and commercializes Prescription Digital Therapeutics to treat diseases with high unmet need.
- B2B
- manufacturing
- health
- biotechnology
- big data
- connected device
- deep tech
- machine learning
- recognition technology
- artificial intelligence
- biotechnology
- core ai
- ai applications
- testing
- entertainment
- oncology
- open source
- aviation and aerospace
- genetics and genomics
- verified unicorns and $1b exits
- predictive analytics
- dna
- neurology
- intellectual property
- medical testing
- surgery
- user behavior
- cardiology and cardiovascular
- genome engineering
- tech for patients
- patient care
- children
- tech for biotech and pharma
- spac ipo announced
- digital therapeutics
- icarus: from unicorn to failure
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
* | N/A | N/A | Bankruptcy |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (73 %) | (56 %) | 225 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (94 %) | (844 %) | (2575 %) | (885 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (27 %) | (1078 %) | (1625 %) | (577 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Pear Therapeutics is a leader in the emerging field of Prescription Digital Therapeutics (PDTs), which are software-based treatments for serious diseases. These therapeutics are designed, tested, and prescribed in a manner similar to traditional drugs but utilize software instead of pills or injections. Pear Therapeutics operates in the healthcare and technology markets, serving patients, healthcare providers, and payers. The company's business model involves developing and delivering clinically validated software that improves patient outcomes, enhances clinician engagement, and offers cost-effective solutions for payers. Revenue is generated through the prescription and use of their digital therapeutics, which are evaluated by the FDA and prescribed by healthcare providers. Pear Therapeutics focuses on integrating biology and software technology to create innovative treatments that are both safe and effective.
Keywords: Prescription Digital Therapeutics, software-based treatments, serious diseases, FDA-evaluated, patient outcomes, clinician engagement, cost-effective, healthcare technology, innovative treatments, clinically validated.